|
|
1 vaccine dose (b)
(n=31)
|
2 vaccine doses (c)
(n=317)
|
|
Age, mean (SD), yr* |
87.2 (9.2) |
85.1 (9.2) |
87.6 (9.2) |
0.22 |
Sex, n (%)**
Female
Male
|
35 (72.9)
13 (27.1)
|
25 (80.7)
6 (19.3)
|
252 (79.5)
65 (20.5)
|
0.56
|
Charlson index (median, IGR) [range] *
|
6.0 (5.0-7.0)
2-15
|
6.0 (5.0-8.0)
3-15
|
6.0 (5.0-7.0)
2-15
|
0.41
|
Prior SARS-CoV-2 positive RT-PCR, n (%)** |
5 (10.4) |
3 (9.7) |
43
(13.6) |
0.82 |
Positive RT-PCR during outbreak, n (%)**
|
21 (43.7)
|
10 (32.3)
|
72 (22.7)
|
0.0059
0.005 (a vs c)
|
N-protein IgG > 0.8 signal to cutoff ratio, n (%)*** |
5
(20.0) |
5 (17.9) |
38 (14.0) |
0.57 |
RBD-IgG level, AU/mL, median (IQR) *
|
n = 26
2 (1-415)
|
n =28
534.00 (201.50 ; 2166.50)
|
n =271
1522.00 (444.00 ; 5389.00)
|
0.000001 0.001 (a vs b)
0.01 (a vs c)
0.08: (b vs c)
|
Covid-19-related deaths, n (%)***
|
5 (10.4)
|
2 (6.4)
|
3 (0.9)
|
0.0007
0.004 (a vs c)
|